Generate Biomedicines, Inc. (GENB)
Nasdaq: GENB · Pharmaceutical Preparations · filing with the SEC since 2025
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal quarter | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|---|---|---|
| Period ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 |
| Report filed | Nov 12, 2026 | Aug 6, 2026 | May 7, 2026 |
| Revenue | 4,220 | 6,314 | 7,224 |
| Research and development | 82,254 | 64,330 | 57,812 |
| General and administrative | 13,473 | 13,598 | 13,524 |
| Total operating expenses | 95,727 | 77,928 | 71,336 |
| Operating income | -91,507 | -71,614 | -64,112 |
| Interest expense | 192 | 155 | 182 |
| Interest and investment income | 4,149 | 4,629 | 2,913 |
| Total non-operating income (expense) | 3,899 | 4,412 | 2,426 |
| Income before income taxes | -87,608 | -67,202 | -61,686 |
| Income tax expense | 49 | 53 | 28 |
| Net income including non-controlling interests | -87,657 | -67,255 | -61,714 |
| Net income to non-controlling interests | 0 | 0 | -268 |
| Net income | -87,657 | -67,255 | -61,446 |
| Net income to common shareholders | -87,657 | -67,255 | -69,195 |
| Earnings per share, basic | -0.68 | -0.52 | -1.07 |
| Earnings per share, diluted | -0.68 | -0.52 | -1.07 |
| Weighted average shares, basic | 128,514,700 | 128,240,371 | 64,871,295 |
| Weighted average shares, diluted | 128,514,700 | 128,240,371 | 64,871,295 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Each quarter is three months. A fourth quarter prints only where the company tagged its three months on their own; the whole year is in the annual view.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income to non-controlling interests the share that belongs to minority holders
us-gaap:NetIncomeLossAttributableToNoncontrollingInterestNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding